Shareholders approve sale of Cumberland's FDA-approved products to Apotex

CUMBERLAND PHARMACEUTICALS INC

Shareholders voted 10,492,455 For (99.84% of votes cast), 15,904 Against, 1,267 Abstain.
Transaction involves sale of FDA-approved commercial products and related assets to Apotex Inc.
Approval allows Cumberland to integrate products with Apotex's U.S. branded business per April 22, 2026 APA.
Special meeting held June 24, 2026; quorum of 70.14% of outstanding shares (10,509,626 shares represented).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.